A group of researchers have disclosed spike glycoprotein (SARS-CoV-2; COVID-19 virus)/ACE2 interaction inhibitors in a new patent.

In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal myoca ...

Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults ...

Sept. 4, 2003 (Vienna) -- Tirofiban, a glycoprotein IIb/IIIa inhibitor, initiated during transport rather than at the hospital is associated with improved initial patency and reduced thrombus ...

Cost and effectiveness of adjunctive therapy with various glycoprotein (GP) IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Treatment with the direct thrombin inhibitor bivalirudin, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while reducing hemorrhagic compl ...

One of the well-established mechanisms of multidrug resistance (MDR) to chemotherapy in cancer patients is ATP binding cassette (ABC) transporter overexpression in cancer cell membrane, and as the ...

Prostate cancer cells that were given this treatment were shown to retain chemotherapy drugs at a much higher level compared to cancer cells not treated with the P-glycoprotein inhibitor.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

The review and re-appraisal of the glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (ACS) has resulted in a revision of the definition of high-risk patients in relation to ...